ArticleJournal of diabetes science and technology2013
Several steps forward: a new meter for multiple patient use.
Article in Journal of diabetes science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Point-of-care (POC) blood glucose testing is becoming ubiquitous in the hospitals because of ease of use, timely results, and cost effectiveness. Historically, these POC devices were designed and regulated for home use by patients with diabetes. Their transition into the hospital multipatient setting has introduced the real risk of cross-contamination and has exposed inadequate accuracy standards. This article highlights some of the current recommendations for these devices and focuses on a new meter that addresses these issues. Although not currently approved for use in the United States, the OneTouch® Verio®Pro blood glucose meter (LifeScan, Inc.), which is the topic of an article by MacRury and coauthors in this issue of the Journal of Diabetes Science and Technology, is a step forward with minimal interferences and good accuracy, and perhaps most importantly, is robust enough to withstand rigorous disinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.